The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.5(GAA):c.1824_1828dup (p.Ala610fs)

CA16041896

370866 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 9dd079f9-ba49-4a93-908f-77d8ea766c37

HGVS expressions

NM_000152.5:c.1824_1828dup
NM_000152.5(GAA):c.1824_1828dup (p.Ala610fs)
NC_000017.11:g.80112647_80112651dup
CM000679.2:g.80112647_80112651dup
NC_000017.10:g.78086446_78086450dup
CM000679.1:g.78086446_78086450dup
NC_000017.9:g.75701041_75701045dup
NG_009822.1:g.16092_16096dup
NM_000152.3:c.1824_1828dup
NM_001079803.1:c.1824_1828dup
NM_001079804.1:c.1824_1828dup
NM_000152.4:c.1824_1828dup
NM_001079803.2:c.1824_1828dup
NM_001079804.2:c.1824_1828dup
NM_001079803.3:c.1824_1828dup
NM_001079804.3:c.1824_1828dup
ENST00000302262.7:c.1824_1828dup
ENST00000390015.7:c.1824_1828dup
ENST00000570716.1:n.264_268dup
ENST00000572080.1:n.212_216dup
ENST00000572803.1:n.438_442dup

Pathogenic

Met criteria codes 4
PVS1 PM3_Supporting PP4 PM2

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
This variant, c.1824_1828dup (p.Ala610AspfsTer88), is a frameshift variant that is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied. The variant is absent in gnomAD v2.1.1, meeting PM2. A patient with infantile onset Pompe disease, meeting the ClinGen LSD VCEP’s specifications for PP4 has been reported who is homozygous for the variant (PMID 24976573). This data meets PM3_Supporting. There is a ClinVar entry for this variant (Variation ID: 370866, 1 star review status) with one submitter classifying the variant as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3_Supporting, PP4.
Met criteria codes
PVS1
This is a frameshift variant which is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied.
PM3_Supporting
A patient with infantile onset Pompe disease and meeting the Clingen LSD VCEP's specifications for PP4 has been described who is homozygous for the variant (PMID 24976573). 0.5 points were given towards PM3. Therefore, PM3_Supporting is met.

PP4
One patient with infantile onset Pompe disease has been described with no detectable GAA activity in dried blood spot samples (PMID 24976573), meeting PP4.
PM2
This variant is absent in gnomAD v2.1.1.
Approved on: 2020-10-29
Published on: 2020-11-12
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.